A new antibody-drug conjugate has eliminated detectable traces of cancer in most patients with a high-risk form of leukemia, offering a potential path to longer remissions and improved survival.
Treatment clears residual disease in 70% of patients
In a Phase 2 study led by researchers at The University of Texas MD Anderson Cancer Center, 70% of patients with B-cell acute lymphoblastic leukemia (ALL) achieved measurable residual disease (MRD) negativity after treatment with inotuzumab ozogamicin. The results, published in Blood Cancer Journal, included strong responses across both Philadelphia chromosome-positive and -negative disease.
Of the 37 patients treated, those who received the therapy earlier in their disease course showed the most favorable outcomes. The study reported a median relapse-free survival of 40 months and a median overall survival of 61 months.
Related: AI platform accelerates discovery of cancer drug candidates
“Our results show that inotuzumab is highly effective at clearing residual disease in patients already in remission, with durable responses and encouraging survival,” said Elias Jabbour, the study’s principal investigator and a professor of leukemia. “This approach has the potential to deepen remissions and change how we manage patients at high risk of relapse.”
Residual disease as a predictor of relapse
MRD refers to the small number of cancer cells that remain in the body after treatment and are detectable only through sensitive testing. When these cells persist, they significantly increase the risk of relapse. Clearing MRD has become a key goal in leukemia treatment, as patients who achieve MRD negativity typically have better long-term outcomes.
The study’s findings suggest inotuzumab ozogamicin could help patients reach a lower-disease state, making them eligible for additional therapies like stem cell transplants or CAR T-cell therapy. The treatment was well tolerated, with manageable side effects, according to the researchers.
Related: AI finds antibiotic candidates in prion proteins
Durable responses and future implications
The study’s authors emphasized that the durability of the responses—with some patients remaining relapse-free for over three years—highlights the potential of inotuzumab ozogamicin to improve long-term survival. While the sample size was relatively small, the results align with previous research suggesting that MRD clearance is a strong predictor of sustained remission.
Further studies will be needed to confirm these findings and determine whether the therapy can be integrated into standard treatment protocols. For now, the data offer a glimpse of a future where residual disease is no longer an inevitable precursor to relapse.
The study was published on June 27.
